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Pathologic effects of the process of nonenzymatic glycation are re-
flected in degenerative changes during ageing, chronic complica-
tions of diabetes mellitus and renal failure, and have also been re-
cognised in some neurologic diseases, such as Alzheimer’s disease.
Aminoguanidine has been extensively studied as an inhibitor of
nonenzymatic glycation, both in vitro and in vivo. We investigated
the inhibiting potency of substituted guanidines in the process of
glycation. For this purpose, -methylguanidine-acetic acid (creatine)
and dimethylbiguanide (Metformin) were chosen. A common fea-
ture of these compounds is the presence of guanidine group in the
molecule. Creatine is a specific muscle tissue metabolite, a non-
toxic biogenic substance. Dimethylbiguanide is a substituted mole-
cule of guanidine structure. In clinical practice, it is used in the
treatment of non-insulin dependent type of diabetes mellitus. Both
agents, -methylguanidine-acetic acid and dimethylbiguanide, tested
at concentrations of 2.5, 5, 10 and 20 mmol L–1, showed a concen-
tration dependent inhibition of the glucose induced albumin glyca-
tion in vitro. The inhibiting effect of substituted guanidines was
somewhat inferior (17%) to the effect of aminoguanidine inhibition
(52%); however, the former substances are valuable for being safe
for human use.
Key words: nonenzymatic glycation, inhibition, creatine, dimethyl-
biguanide.
* Author to whom correspondence should be addressed. (E-mail: zturk@idb.hr)
CROATICA CHEMICA ACTA CCACAA 74 (2) 455¿465 (2001)
INTRODUCTION
The ability of reducing sugars to react with amines as well as with basic
amino groups of proteins and nucleic acids without enzyme mediation is a
phenomenon known as nonenzymatic glycation. This is a classic covalent re-
action whereby a sugar-protein complex is formed by N-glycoside linkage.
The reactions of nonenzymatic glycation were described by Maillard, a
French chemist, and have thus been named after him. Maillard’s reactions
have been extensively studied in food chemistry, however, it was only in the
’70s that they were detected to occur also in vivo.1 In physiologic conditions,
nonenzymatic glycation can be detected in the process of ageing, however,
the reactions are considerably faster and more intensive in the pathophysio-
logic conditions (e.g., diabetes mellitus) associated with a persistently ele-
vated concentration of glucose.2 The pathologic effects of nonenzymatic
glycation are reflected in chronic complications of diabetes mellitus, renal
failure, degenerative changes occurring in the course of ageing, and have
also been identified in some neurologic diseases.3
Maillard’s reactions are very complex and multilevel, and can be ana-
lysed in three stages. In the first stage, glycosamine, i.e. unstable Schiff ’s
base, is formed. This is followed by cyclisation and isomerisation, known as
Amadori’s rearrangement, whereby the compound 1-amino-deoxyketose, fre-
quently called Amadori’s compound, is formed. It is an early product of non-
enzymatic glycation; an intermediary acting as a precursor of all compounds
subsequently formed in the process of glycation.1,4 The second stage or in-
termediary stage reactions include formation of numerous intermediary pro-
ducts. Amadori’s compound can be degraded by the reaction of autocatalysis,
and by dehydrations, oxidation, cleavage or rearrangements, when 1,2 or 2,3
enols and a number of secondary products, such as aldehydes, dicarbonyls
and reductones, are formed from the carbohydrate moiety. These diverse in-
termediaries repeatedly participate in further steps of the reaction by form-
ing various compounds.4 The third, end stage includes complex reactions of
polymerisation of the products formed in the second reaction stage, whereby
heterogeneous structures commonly termed advanced glycation endproducts
(AGE) are formed.2 Some of the second-stage intermediary products enter
the end stage of Maillard’s reaction, when very complex polymerisations occur
to form complex AGE structures. AGE formation can be very conveniently
illustrated by means of 3-deoxyglucosone, which is formed by Amadori’s
compound deamination. Deoxyglucosone is just one of the intermediary pro-
ducts formed in the cascade of Maillard’s reactions. However, it is an impor-
tant intermediary because of its high reactivity,4 since it further reacts with
terminal neucleophilic amino groups of lysine or arginine, thus forming com-
plex polymers that contain pyrraline and imidazolone structures. Generally,
AGEs are characterised by great structural and physicochemical diversity.
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Thus, some AGEs are fluorescent polymers, e.g., pentosidine, crosslines and
imidazolones, whereas others are neither fluorescent nor have a reticulated
structure, e.g., pyrraline, N-lactatolysine and N-(carboxymethyl) lysine.4
Attempts have been made to pharmacologically influence the process of
nonenzymatic glycation in order to prevent or slow down the formation of
glycation products. There are two main pharmacological approaches. One in-
cludes inhibition of the rearrangement of early into endproducts of glycation,
so as to prevent the rearrangement of early, still reversible compounds into
the end, irreversible and crosslinked products.5 The other approach is based
on the attempted cleavage of the already formed AGE products. The best-
known AGE breaker is phenacyl tiazole bromide (PTB), which can break co-
valent bonds of crosslinked AGE products. AGE breakers have currently
been intensively investigated.6
Aminoguanidine hydrochloride, a nucleophilic hydrazine compound, con-
tains a terminal amino group, which is of higher chemical reactivity than
terminal amino groups of proteins. For this feature, aminoguanidine has
been chosen as an inhibitor of glucose binding to proteins. Aminoguanidine
has been found to inhibit formation of AGE products, primarily by reacting
with Amadori’s products, i.e. by blocking the carbonyl groups on ketoamines
and their derivative.7 Besides, aminoguanidine reacts specifically also with
AGE peptides and other reactive intermediaries, thus preventing their bind-
ing to free amino groups. Numerous animal studies have shown that amino-
guanidine might prevent or at least slow down the development of late com-
plications in diabetes mellitus.8,9 It compromises collagen crosslinking; acts
on vascular changes in the retina, peripheral nerves, aorta, kidneys and skin;
decreases albuminuria; and reduces early structural changes in the vascu-
lar system and electrophysiologic changes in peripheral nerves. It has an in-
hibitory effect on precipitated development of diabetic retinopathy and for-
mation of thrombi. Also, aminoguanidine decreases the content of AGE in
the glomerular basal membrane and prevents its thickening. According to
recent studies, aminoguanidine inhibits the activity of NO synthase. Although
quite encouraging data on the effect of aminoguanidine have been reported
by previous studies, clinical trials have not yet yielded as promising results
as expected.
In the present study, we have tried to evaluate the potency of substituted
guanidines, i.e. methylguanidines, as nonenzymatic glycation inhibitors. We
used -methylguanidine-acetic acid (creatine) and dimethylbiguanide (Met-
formin). A common feature of these compounds is the presence of guanidine
group in the molecule (Figure 1). Creatine is a specific muscle tissue metab-
olite, a non-toxic biogenic substance. Dimethylbiguanide is a substituted
molecule of guanidine structure, used in clinical practice for the treatment
of non-insulin dependent diabetes mellitus.10
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MATERIAL AND METHODS
Bovine serum albumin (Sigma: A-7906), creatine anhydrous, 1,1-dimethylbiguanide
hydrochloride, aminoguanidine bicarbonate, D,L-arginine and L-lysine were purchased
from Sigma, St Louis, USA. D-Glucose and all other chemicals were from Merck,
Darmstadt, Germany.
Glycated protein was prepared in vitro by incubation of bovine serum albumin
(BSA) and D-glucose. BSA was dissolved in 0.2 mol L–1 phosphate buffer, pH 7.4, in a
concentration of 10 mg mL–1 containing 3 mmol L–1 NaN3, 5 mmol L–1 EDTA-Na and
penicillin-VK 100 U mL–1. The reaction mixture was sterilised by filtration (0.45 m
pore filter) and allowed to incubate in dark at 37 °C for up to 21 days. Formation of
glycated products was monitored by fluorescence spectrophotometry, on a daily basis
continuously for three weeks. Fluorescence values of the samples were measured at
a protein concentration of 5–10 mg mL–1, and expressed in arbitrary units of fluores-
cence per mg protein. All readings were corrected for the blank value recorded in the
preparation of albumin, incubated in the absence of D-glucose.
In the experiments on the potential inhibitory action, aminoguanidine, dimethyl-
biguanide, and creatine were incubated in a reaction mixture of albumin and glu-
cose. The inhibitory effect of creatine was tested at concentrations of 2.5, 5, 10 and
20 mmol L–1. Dimethylbiguanide was tested at concentrations of 5 and 10 mmol L–1,
and aminoguanidine at 2.5, 5 and 10 mmol L–1. Reaction mixtures were sterilised by
filtration (0.45 m pore filter) and allowed to incubate in dark at 37 °C. Fluorescence
intensity was measured in 1 mL of incubation mixture dissolved with 1 mL phos-
phate buffer, pH 7.4. Relative fluorescence was recorded on a Perkin-Elmer LS-5B
luminescence spectrometer at a) 440 nm upon excitation of 370 nm for Maillard
products related fluorescence, and b) 335 nm excitation and 385 nm emission for
pentosidine-like products. A native BSA preparation (1 mg mL–1 in phosphate buffer,
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Figure 1. The structure of guanidine, aminoguanidine, creatine and dimethylbiguanide.
pH 7.4) was used as reference, and its fluorescent intensity was defined as one unit
of fluorescence. The result was expressed in arbitrary units representing measured
fluorescence per mg BSA (FU mg–1). Measurements were made in comparison with ap-
propriate blanks of 0.2 mol L–1 phosphate buffer, pH 7.4, containing bovine serum al-
bumin (BSA) alone, as well as a separate individual blank for each of the tested inhib-
itors. The fluorescence level of samples was corrected against the fluorescence of
complete reagent blanks for BSA plus the tested inhibitors in increasing concentra-
tions but without glucose.
Protein content was determined in each sample according to Bradford. Protein
determination by this micromethod is based on protein reaction with Coomassie
Brilliant Blue G-250. Upon stain binding to the protein, the colour changes from red
to blue, i.e. maximal absorption changes from 465 to 595 nm.
RESULTS
Glycated albumin was prepared in vitro by incubation of BSA with glu-
cose at concentrations of 20 and 100 mmol L–1. During 21-day incubation,
fluorescence of the reaction mixtures was measured at regular intervals on
days 0, 7, 14 and 21, at excitation/emission of 335/385 and 370/440 nm. For-
mation of fluorophore was linearly dependent on the reaction time and
sugar concentration.
The inhibitory effect of creatine on nonenzymatic glycation of albumin
(with 20 mmol L–1 glucose) was assessed upon addition of creatine to the re-
action mixture, in concentrations of 5 and 10 mmol L–1. At the beginning of
the experiment and on day 7 of incubation, the level of fluorescence of incu-
bation mixtures with creatine was 28 FU mg–1, measured at ex/em 370/440
nm. On day 14, a slight fluorescence increase to 37.8  0.7 FU mg–1 was re-
corded, however, without any major difference between the samples with 5
and 10 mmol L–1 creatine. On day 21, the fluorescence of the reaction mix-
tures containing 5 and 10 mmol L–1 creatine was 72.2  3.6 and 67.7  3.1
FU mg–1, respectively, the latter being significantly lower (p < 0.001) than
the fluorescence of the control reaction mixture of albumin and glucose with-
out addition of guanidine compound (81.6  2.9 FU mg–1). These data sug-
gest that creatine could prevent formation of fluorescent compounds formed
in the non-catalysed reaction of albumin and glucose. The inhibitory effect
of 5 and 10 mmol L–1 creatine was 11% and 17%, respectively. The inhibi-
tory effect of creatine was analysed in a wider concentration range of 2.5, 5,
10 and 20 mmol L–1 after 16 days of incubation. Fluorescence of the albumin
and glucose reaction mixture without addition of creatine was taken as a
measure of 100% glycated albumin formation. A 10% inhibitory effect was
observed for creatine concentrations of 2.5 and 5 mmol L–1, while its concen-
tration of 10 mmol L–1 showed a stronger, 14% inhibitory effect. Creatine
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concentration of 20 mmol L–1 produced the strongest inhibitory effect on
fluorophore formation, reducing it by 35% (Figure 2). Accordingly, the inhib-
itory effect of creatine was found to depend on the concentration used. The
effect of creatine (10 mmol L–1) on nonenzymatic glycation of bovine albu-
min with a very high glucose concentration of 100 mmol L–1 was tested as
well. Fluorescence was measured at the beginning, and on day 14 and 21.
The level of fluorescence of the reaction mixture of albumin and glucose
showed a tendency to steady increase. At the same time, the fluorescence of
the albumin and glucose mixture with addition of creatine was also ob-
served to rise, however, at a slower rate. At the end of the experiment, fluo-
rescence of 76.9  0.5 FU mg–1 was measured for the albumin and glucose
mixture with addition of creatine, which was significantly lower (p < 0.01)
than the fluorescence of the albumin and glucose reaction mixture without
inhibitor addition. Comparison of the inhibitory effect of 10 mmol L–1
creatine on albumin glycation in incubation with 20 and 100 mmol L–1 glu-
cose indicated that the increase in the concentration of glucose had no lin-
ear effect on the process of nonenzymatic glycation. Thus, the inhibitory ef-
fect of creatine, measured as fluorescence reduction, ranged between 15%
and 20% in both cases of albumin glycation.
The effect of dimethylbiguanide on nonenzymatic albumin glycation is pre-
sented in Figure 3. Dimethylbiguanide in concentrations of 5 and 10 mmol L–1
was incubated for three weeks in mixtures of albumin and 20 mmol L–1
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Figure 2. The inhibitory effect of creatine on the formation of fluorescent products
(measured at 370/440 nm ex/em) of noncatalysed glycation after 16-day incubation of
reaction mixtures containing albumin (A 10 mg mL–1), glucose (G 20 mmol L–1) and
creatine (C) in concentrations of 0, 2.5, 5, 10 and 20 mmol L–1.
AG = albumin + glucose; AG+C = albumin, glucose + creatine (conc.).
glucose. On day 7, the reaction mixtures with either dimethylbiguanide
concentration showed no change from the initial fluorescence value. On day
14, the sample with 5 mmol L–1 dimethylbiguanide retained the same level of
fluorescence, and on day 21 it increased to 79.6  8.0 FU mg–1. With this in-
crease, the measured fluorescence approached the value of 81.6  2.9
FU mg–1, measured in the mixture of albumin and glucose without inhibitor
addition. On day 14, parallel incubation of albumin and glucose with 10
mmol L–1 dimethylbiguanide showed a fluorescence intensity of 39.5  6.5
(p < 0.05 vs AG), with a tendency to further increase. At the end of the ex-
periment, on day 21, fluorescence of 67.4  6.7 FU mg–1 was recorded, which
was significantly lower than the fluorescence of the albumin and glucose mix-
ture (p < 0.001) without addition of a potential inhibitor. These results indi-
cated the inhibitory effect of dimethylbiguanide to depend on the concentra-
tion used. On day 21, a dimethylbiguanide concentration of 5 mmol L–1
showed no major inhibitory effect, however, a two-fold concentration of 10
mmol L–1 dimethylbiguanide was effective and lowered the level of fluores-
cence by 17%.
Our studies to date have shown that creatine and dimethylbiguanide have
an inhibitory effect on nonenzymatic glycation of protein. Aminoguanidine
has been demonstrated to inhibit rearrangement of early into endproducts
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Figure 3. Nonenzymatic glycation derived fluorescence during 21-day incubation of
reaction mixtures consisting of albumin (A 10 mg mL–1), glucose (G 20 mmol L–1)
and dimethylbiguanide or creatine, both in concentrations of 5 and 10 mmol L–1. Re-
sults are presented as the mean (SD) of 10 measurements. Relative fluorescence
was recorded at 440 nm upon excitation of 370 nm.
AG vs AG + dimethylbiguanide 5 mmol L–1, NS.
AG vs AG + dimethylbiguanide 10 mmol L–1, p < 0.001.
of glycation. Therefore, our experiment was designed so as to measure in
parallel the inhibitory potential of creatine, dimethylbiguanide and amino-
guanidine. Albumin was chosen as the target molecule for nonenzymatic
glycation. Glucose concentration of 20 mmol L–1 corresponded to physiologic
hyperglycemia. The mentioned inhibitors were individually added to the
reaction mixtures of protein and sugar, each in a concentration of 10 mmol L–1.
The values of fluorescence measured after three-week incubation are shown
in Figure 4. Aminoguanidine was found to be the most potent inhibitor. Af-
ter two-week incubation, the samples containing aminoguanidine showed no
fluorescence increase, whereas the other two inhibitors failed to be as effi-
cient. However, in three weeks of incubation, characterised by intensive for-
mation of nonenzymatic glycation endproducts, the following results were
recorded: aminoguanidine inhibited 52% of the fluorescent product forma-
tion, while creatine and Metformin had a comparable inhibitory effect, so
that both of these guanidine compounds decreased the level of fluorescence
by 17%.
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Figure 4. Comparison of the inhibitory effect of aminoguanidine, creatine and
dimethylbiguanide (10 mmol L–1 each) during nonenzymatic glycation of albumin (A
10 mg mL–1) with glucose (G 20 mmol L–1). Results are presented as the mean (SD)
of 10 measurements. Fluorescence was measured at a wavelenght of 370/440 nm (ex-
citation/emission). * p < 0.001; ** p < 0.0001.
DISCUSSION
Pharmacologic agents that specifically inhibit the process of nonenzymatic
glycation have been mostly investigated in terms of delaying the develop-
ment and progression of diabetes related complications. Aminoguanidine, a
nucleophilic hydrazine of a guanidine structure, was the first and so far the
best investigated agent. Aminoguanidine generally reacts with intermediary
products of the second-stage Maillard’s reaction that are not bound to protein
structure, such as 3-deoxyglucosone.7 In vitro experiments have also demon-
strated that aminoguanidine removes hydroxyl free radicals, and according
to some authors, prevents lipid peroxidation in vivo. There is ample evidence
confirming that the treatment with aminoguanidine in experimental diabe-
tes reduces the micro- and macrovascular disease.8 However, due to its side
effects, there seem to be some problems with the use in humans. Phase II/III
clinical trials, conducted for some time now, have not yet produced any
promising report.11 This has stimulated us to embark upon this study, to see
whether some other guanidine substances might have an inhibitory effect in
the process of glycation. We chose -methylguanidine-acetic acid (creatine)
and dimethylbiguanide (Metformin) containing a guanidine structure in its
molecule and with a substituted molecule moiety. These compounds were
chosen primarily for their possible use in humans. Thus, -methylguanidine-
acetic acid or creatine is a biogenic guanidine compound found in muscular
tissue, where it is involved in the formation of high-energy ATP.12 There are
also reports on its hypoglycemic action.13 Like aminoguanidine, creatine has
a terminal nucleophilic amino group. Dimethylbiguanide is a substituted mo-
lecule of a guanidine structure, which was years ago demonstrated to have a
hypoglycemic effect. Dimethylbiguanide or Metformin has been widely used
in clinical practice for the treatment of non-insulin dependent diabetes melli-
tus. Results of a recent study suggest that Metformin is efficient in scaveng-
ing reactive carbonyls, the intermediaries produced during Maillard’s reac-
tions.14,15
During in vitro and in vivo nonenzymatic glycation of proteins, numer-
ous products are formed, which are characterised by great structural and
physicochemical diversity. The great heterogeneity of glycated products poses
considerable difficulties in the attempts at their qualitative and quantita-
tive determination. In the present study, we measured the glycation prod-
uct-derived fluorescence as a palliative parameter, yielding a relative differ-
ence in the intensity of nonenzymatic glycation. In all our experiments, we
used bovine serum albumin as a target molecule of nonenzymatic glycation
at high glucose concentrations in semiphysiologic conditions and identical in
vitro glycation conditions. The results indicated both creatine and Metformin
to be potential inhibitors in the process of nonenzymatic glycation. The effi-
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ciency of inhibition depended on the guanidine substance concentration, so
a more potent inhibitory effect was obtained by increasing the concentration
of creatine (2.5, 5, 10 and 20 mmol L–1). The most potent inhibition of 35%
was measured with a creatine concentration of 20 mmol L–1. Dimethylbigua-
nide showed a similar pattern. A concentration of 10 mmol L–1 lowered the
level of fluorescence in the incubation mixture by 17%. It should be noted
that similar rates of inhibition were invariably recorded at various glucose
concentrations. The increase in the glucose level from 20 to 100 mmol L–1
did not reduce the inhibitory action of creatine. Even at an artificially high
glucose concentration of 100 mmol L–1, the inhibitory effect of 5 and 10
mmol L–1 creatine remained the same, i.e. between 15% and 20%, thus defi-
nitely confirming our preliminary results.16 However, the effect of inhibition
with substituted guanidines, creatine and Metformin, was considerably lower
than that recorded with aminoguanidine. This comes as no surprise, because
the structure of substituted guanidines reveals that they have fewer nucleo-
philic terminal amino groups. In spite of this, the results presented should
not be disregarded, primarily because the substances tested in this study
are safe for human use, and it may prove plausible to evaluate them in a
clinical trial. It has been long known that muscular activity improves the
tolerance of glucose load, and that the level of blood glucose decreases with
exercise. As creatine is a specific muscle tissue metabolite, its synthesis be-
ing intensified with enhanced muscular activity, we could speculate on the
possible involvement of the inhibitory mechanisms of nonenzymatic glycation
in this phenomenon.
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Supstituirani guanidini kao inhibitori u neenzimskom
glikoziliranju in vitro
Irena Mi{ur i Zdenka Turk
Patolo{ki u~inci {to ih proces neenzimskog glikoziliranja poti~e in vivo ogledaju
se tijekom starenja u komplikacijama {e}erne bolesti, bubre`noj insuficijenciji, a za-
bilje`eni su i u nekim neurolo{kim bolestima. Aminoguanidin je bio prvi i do sada
najbolje prou~avan inhibitor Maillardovih reakcija. No in vivo su zapa`ena i njegova
{tetna djelovanja. Stoga se u ovom radu `eljelo utvrditi mogu li supstituirani guanidini,
koji nisu {tetni za humanu primjenu, inhibirati reakcije neenzimskog glikoziliranja.
U tu su svrhu izabrani -metilguanidino-octena kiselina (kreatin) i dimetilbiguanid
(Metformin), jer oba spoja uklju~uju guanidinsku strukturu. Kreatin je specifi~an
mi{i}ni metabolit, dakle netoksi~na biogena supstancija. Dimetilbiguanid je supsti-
tuirana molekula guanidinske strukture, a u klini~koj se praksi koristi kao oralni
hipoglikemik. Oba su spoja primijenjena u koncentracijama 2,5; 5; 10 i 20 mmol L–1,
pri semifiziolo{kom inkubiranju ljudskog albumina s glukozom i pokazali su inhi-
bicijski u~inak. Zabilje`ena relativna inhibicija (17%) bila je ni`a od u~inka amino-
guanidina (52%).
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